Multiple Myeloma News & Features
A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.
Researchers believe that a staple of Earth science research can be used in biomedical settings to predict the course of disease.
Genetically modifying immune cells might effectively treat multiple myeloma, according to a new study.
Blacks may be twice as likely as whites to develop multiple myeloma because they are more likely to have a precursor condition known as monoclonal gammopathy of undetermined significance.
The most comprehensive genetic study to date of the blood cancer multiple myeloma has revealed that the genetic landscape of the disease may be more complicated than previously thought.
Multiple Myeloma Clinical Trials
- Study investigating advanced MRI scans to detect prostate cancer set to begin
- TNF-alpha inhibitors associated with uveal melanoma
- Improved survival in pediatric umbilical cord transplants for hematologic cancers
- Most internet sites on prostate cancer disagree with expert panel's recommendations
- Radiation exposure linked to aggressive thyroid cancers
- A New Era is Coming up in the Treatment of Chronic Lymphocytic Leukemia
- Early palliative care can cut hospital readmissions for cancer patients
- ONA Interview: Breaking the barriers to effective palliative care
- Fluorescent tattoos may improve self-esteem in patients receiving radiotherapy for breast cancer
- Cancer prehabilitation: One step toward improved outcomes
- CT lung screening appears cost-effective
- Collaboration yields new methods to treat tumors with antennas
- Classifying gene mutations in neuroblastoma may point to improved treatments
- International study shows wide differences in 5-year survival rates across the globe
- Diagnostic grading system developed for cancer-related weight loss
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|